Streetwise Reports' Article Archives — October 2019 back to current month (34)
Tech Firm Partners With Pharmacy, Diabetes Management Entities (10/31/2019)
The Canadian company will provide its remote patient monitoring and chronic care management software solutions to these two U.S. enterprises.
Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results (10/29/2019)
Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study.
New Data Could Drive Use of Pancreatic Cancer Early Detection Test (10/29/2019)
The recent results and their implications are provided in an H.C. Wainwright & Co. report.
Tech Firm Releases Telemedicine Product Aiding Senior Care, Safety (10/28/2019)
The package encompasses wearable devices, two-way video communication and geofencing.
IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data (10/28/2019)
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura.
ResMed Shares Set 52-Week Intraday High Price After Posting Q1 Earnings (10/25/2019)
Shares of respiratory medical device maker and software applications company ResMed Inc. traded 15% higher at times today after the firm posted positive Q1/20 earnings results.
Varian Shares Trade Higher on Yearly Earnings and FY/20 Guidance (10/24/2019)
Shares of Varian Medical Systems traded 10% higher at times today after the company reported quarterly and annual earnings. The company increased revenue 10% year-over-year and provided FY/20 guidance.
Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses' (10/23/2019)
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report.
Mobile Health Solutions Provider Adds Clients in Multiple States, Verticals (10/23/2019)
The primary aim of the firm's technology platform is to support remote patient monitoring.
Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases (10/23/2019)
These therapeutic candidates add to those already in the firm's pipeline.
Boston Scientific Reports 13% Q3 Sales Growth and Raises Yearly Estimates (10/23/2019)
This morning shares of Boston Scientific traded 6% higher after the firm reported a 13.1% increase in revenue for Q3/19. The firm also raised its revenue guidance for both Q4/19 and FY/19.
Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings (10/22/2019)
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today.
Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis (10/21/2019)
The details of this study and a second one are outlined in a ROTH Capital Partners report.
Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher (10/18/2019)
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference.
Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data (10/17/2019)
Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease.
Healthcare Tech Firm Signs Five New Clients in Texas (10/16/2019)
The company just landed another five clients in Texas and now plans to build out sales teams in five additional states.
Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer (10/16/2019)
Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met.
Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho (10/16/2019)
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close.
Healthcare Company to Use IBM's Watson AI in Telemedicine App (10/15/2019)
The goal is to reduce the time healthcare workers spend on mundane tasks and thereby improve patient care.
Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results (10/15/2019)
Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility.
Technical Analyst Expects Health Technologies Firm to Break Higher (10/14/2019)
Technical analyst Clive Maund outlines the reasons this stock might break higher.
Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million (10/14/2019)
Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal.
Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company (10/12/2019)
Technical analyst Clive Maund believes this stock could gain traction soon.
Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights (10/11/2019)
Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie.
Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid (10/10/2019)
Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal.
Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference (10/09/2019)
Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Meeting.
Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial (10/08/2019)
Data from this study should be released by the end of this year.
Coverage Initiated on U.S.-Based Precision Therapy Developer (10/08/2019)
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report.
JV with Moosehead Breweries Readying Cannabis-Infused Beverages for Commercialization (10/08/2019)
Progress has been made in all areas, from testing the product to evaluating distributors.
Healthcare Tech Company Switches to EY Blockchain Platform (10/07/2019)
This will help its customers access the products and tools they need more sustainably.
Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% (10/07/2019)
Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases.
Healthcare Tech Firm Expands Patient Base in Texas (10/04/2019)
The company landed five new U.S. facilities as customers.
PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial (10/03/2019)
This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection.
Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders (10/02/2019)
Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec